JS Link, Inc. (127120.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩18,160 (+5.83%) as of
Key statistics
- Market cap
- 630.90B
- Dividend yield
- 0.00%
- 52-week range
- 13,860.00 – 49,900.00
- Beta
- 0.58
- Revenue (TTM)
- 22.78B
- Profit margin
- -23.26%
- Volume
- 159.26k
About JS Link, Inc.
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In addition, it provides rare earth and permanent magnets. The company was formerly known as DNA Link, Inc. and changed its name to JS Link, Inc. in April 2025. JS Link, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seoul, South Korea
- Employees
- 146
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.